IL-17A blockade reduces T-cell signatures, dendritic cell signatures, and keratinocyte hyperproliferation signatures and increases regulatory molecular expression in psoriasis lesional skin at total skin transcriptome levels. The gene discussed is IL17A; the disease is psoriasis.